Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2006 1
2016 1
2017 1
2019 1
2020 1
2021 3
2022 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
Blixt L, Gao Y, Wullimann D, Murén Ingelman-Sundberg H, Muschiol S, Healy K, Bogdanovic G, Pin E, Nilsson P, Kjellander C, Grifoni A, Sette A, Sällberg Chen M, Ljunggren HG, Buggert M, Hansson L, Österborg A. Blixt L, et al. Blood. 2022 Dec 1;140(22):2403-2407. doi: 10.1182/blood.2022016815. Blood. 2022. PMID: 36150168 Free PMC article. No abstract available.
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
Blixt L, Wullimann D, Aleman S, Lundin J, Chen P, Gao Y, Cuapio A, Akber M, Lange J, Rivera-Ballesteros O, Buggert M, Ljunggren HG, Hansson L, Österborg A. Blixt L, et al. Haematologica. 2022 Apr 1;107(4):1000-1003. doi: 10.3324/haematol.2021.280300. Haematologica. 2022. PMID: 35045694 Free PMC article. Clinical Trial. No abstract available.
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Blixt L, Bogdanovic G, Buggert M, Gao Y, Hober S, Healy K, Johansson H, Kjellander C, Mravinacova S, Muschiol S, Nilsson P, Palma M, Pin E, Smith CIE, Stromberg O, Sällberg Chen M, Zain R, Hansson L, Österborg A. Blixt L, et al. Leukemia. 2022 Feb;36(2):476-481. doi: 10.1038/s41375-021-01424-w. Epub 2021 Sep 25. Leukemia. 2022. PMID: 34564699 Free PMC article.
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.
Ingelman-Sundberg HM, Blixt L, Wullimann D, Wu J, Gao Y, Healy K, Muschiol S, Bogdanovic G, Åberg M, Kjellander C, Grifoni A, Sette A, Aleman S, Chen P, Blennow O, Hansson L, Ljunggren HG, Chen MS, Buggert M, Österborg A. Ingelman-Sundberg HM, et al. Among authors: blixt l. Haematologica. 2024 Feb 1;109(2):646-651. doi: 10.3324/haematol.2023.282894. Haematologica. 2024. PMID: 37646668 Free PMC article. No abstract available.
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Smith CIE, Wullimann D, Vesterbacka J, Lindgren G, Blixt L, Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini D, Norlin AC, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K, Chen MS, Buggert M, Ljunggren HG, Ljungman P, Aleman S; COVAXID-collaborator group (shown separately). Bergman P, et al. Among authors: blixt l. EBioMedicine. 2021 Dec;74:103705. doi: 10.1016/j.ebiom.2021.103705. Epub 2021 Nov 30. EBioMedicine. 2021. PMID: 34861491 Free PMC article. Clinical Trial.
[An unusual case].
Blixt L. Blixt L. Lakartidningen. 2006 Jul 12-25;103(28-29):2164. Lakartidningen. 2006. PMID: 16897847 Swedish. No abstract available.
12 results